



## Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7

BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 23, 2020-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first quarter 2020 financial results after the close of the market on Thursday, May 7, 2020 and hold its investor conference call on the same day, Thursday, May 7, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the "Investor Relations" section of Anika's website, [www.anikatherapeutics.com](http://www.anikatherapeutics.com). An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

[Anika Therapeutics, Inc.](http://www.anikatherapeutics.com) (NASDAQ: ANIK) is a global, integrated joint preservation and regenerative therapies company based in Bedford, Mass. Anika is committed to delivering therapies to improve the lives of patients across a continuum of care from osteoarthritis pain management to joint preservation and restoration. The company has more than two decades of global expertise commercializing more than 20 products based on its proprietary [hyaluronic acid \(HA\) technology platform](#). For more information about Anika, please visit [www.anikatherapeutics.com](http://www.anikatherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200423005145/en/): <https://www.businesswire.com/news/home/20200423005145/en/>

For Investor Inquiries:

Anika Therapeutics, Inc.

Sylvia Cheung, 781-457-9000

Chief Financial Officer

[investorrelations@anikatherapeutics.com](mailto:investorrelations@anikatherapeutics.com)

For Media Inquiries:

W2O Group

Jeremy Berrington, 312-241-1995

[jberrington@w2ogroup.com](mailto:jberrington@w2ogroup.com)

Source: Anika Therapeutics, Inc.